Peanut (<i>Arachis hypogaea</i>) Allergen Powder-dnfp: The First FDA-approved Oral Immunotherapy for Desensitization of Peanut Allergy in Children

Smith, Sarah S; Hilas, Olga

doi:10.5863/1551-6776-26.7.669

Cited by 8 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given this circumstance, the use of sFcεRI as a stand-alone biomarker might be limited, but could, maybe together with other factors, give a clearer picture of the allergic status of a patient and might be of use as a follow up marker during tolerance induction, for example, with the newly developed oral immunotherapy for peanut sensitized children. 47 This project was set out as an exploratory study with low patient numbers and a retrospective cross-sectional single center study design.…”

Section: Discussionmentioning

confidence: 99%

“…As third pathophysiological possibility, also, both mechanisms could be present in food allergic patients depending on the atopic background and the status of the allergy. Given this circumstance, the use of sFcεRI as a stand‐alone biomarker might be limited, but could, maybe together with other factors, give a clearer picture of the allergic status of a patient and might be of use as a follow up marker during tolerance induction, for example, with the newly developed oral immunotherapy for peanut sensitized children 47 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble IgE‐binding factors in the serum of food‐allergic patients: Possible pathophysiological role of soluble FcεRI as protective factor

Steinert

Moñino-Romero

Butze

et al. 2023

Clinical & Translational All

View full text Add to dashboard Cite

Background IgE‐mediated food allergy is the result of an aberrant immune response involving the interaction of a food allergen with its specific IgE bound to FcɛRI, the high affinity IgE receptor, on mast cells. Allergen‐specific IgE also binds to soluble binding factors, but, their expression and role in food allergy is not well characterized. Here, we assess the prevalence and relevance of soluble IgE binding factors in food allergy and tolerance. Methods We measured serum levels of four IgE binding factors, that is, galectin‐3, galectin‐9, soluble FcɛRI (sFcεRI) and soluble CD23 (sCD23) in 67 adults sensitized to peanut or hazelnut and sFcɛRI in 29 children sensitized to hen's egg. Adults without food allergen sensitization ( n = 17) served as healthy controls. We compared serum levels of patients and controls and assessed them, in the former, for links to clinical features including allergy and tolerance. Results Serum levels of sFcɛRI and sCD23, but not galectin‐3 and galectin‐9, significantly differ in food‐sensitized patients as compared to healthy controls. A subgroup (28%) of peanut and hazelnut allergic patients had elevated sFcεRI levels, that were associated with higher total and specific IgE levels. Furthermore, sFcεRI levels were significantly higher in tolerant subjects compared to allergics. Among hazelnut allergic patients, those with high sFcεRI levels tolerated the highest protein amounts in the oral food challenge. Conclusion sFcɛRI but not sCD23, galectin‐3 and galectin‐9 might play a role in the pathophysiology of food allergy. Its functional role or use as biomarker should be assessed in further studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Soluble IgE‐binding factors in the serum of food‐allergic patients: Possible pathophysiological role of soluble FcεRI as protective factor

Steinert

Moñino-Romero

Butze

et al. 2023

Clinical & Translational All

View full text Add to dashboard Cite

show abstract

“…While allergies to cow's milk or chicken egg proteins may resolve naturally during adolescence, allergy to peanut frequently persists into adulthood ( 88 ). Physical or chemical processes can be employed to reduce the allergenicity of peanuts and peanut products, however, avoidance or allergen immunotherapy [e.g., oral immunotherapy, Palforzia ( 89 )] are recommended for sensitized individuals ( 90 , 91 ). Several major peanut allergens have been identified including glycoprotein Ara h 2, which is recognized by IgE antibodies in more than 90% of peanut-allergic individuals ( 92 , 93 ).…”

Section: Crispr Gene Editing Of Allergensmentioning

confidence: 99%

New Frontiers: Precise Editing of Allergen Genes Using CRISPR

2022

View full text Add to dashboard Cite

Genome engineering with clustered regularly interspaced short palindromic repeats (CRISPR) technology offers the unique potential for unequivocally deleting allergen genes at the source. Compared to prior gene editing approaches, CRISPR boasts substantial improvements in editing efficiency, throughput, and precision. CRISPR has demonstrated success in several clinical applications such as sickle cell disease and β-thalassemia, and preliminary knockout studies of allergenic proteins using CRISPR editing show promise. Given the advantages of CRISPR, as well as specific DNA targets in the allergen genes, CRISPR gene editing is a viable approach for tackling allergy, which may lead to significant disease improvement. This review will highlight recent applications of CRISPR editing of allergens, particularly cat allergen Fel d 1, and will discuss the advantages and limitations of this approach compared to existing treatment options.

show abstract

“…This study demonstrated that consistent OIT treatment with PP could lead to decreased sensitivity to peanut allergen exposure. This led to the US Food and Drug Administration (FDA) approval of the first peanut- derived OIT treatment: Palforzia [57]. With the adoption of the first and only FDA-approved PP in the USA for OIT treatment, Palforzia will next become available for treatment in the UK.…”

Section: Immunotherapymentioning

confidence: 99%

Current insights: a systemic review of therapeutic options for peanut allergy

O’Rourke¹,

Tang²,

Chin³

et al. 2022

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of reviewWith increasing prevalence of peanut allergy (PA) globally and the greater risk of potential reactions occurring due to the leading role of nuts in food products, PA has become a significant public health concern over the past decade, affecting up to 5 million of the US adult population. This review details updates and advances in prevalence, diagnosis, and immunotherapies that have occurred over the past year.Recent findingsTherapeutic and diagnostic advances remain at the forefront of research and have continued to push the food allergy (FA) field forward to provide a promising role in the detection and treatment of PA. The FA field has researched significant advances in peanut immunotherapy, biomarker diagnosis, and quality of life (QoL) improvement.SummaryGiven the burden and consequences for individuals with PA, these advances delivered in clinical practice can significantly improve the QoL of individuals with PA and their caregivers. Ongoing studies will continue to investigate long-term outcome measures of desensitisation and effective management plans tailored to the families’ needs.

show abstract

Peanut (Arachis hypogaea) Allergen Powder-dnfp: The First FDA-approved Oral Immunotherapy for Desensitization of Peanut Allergy in Children

Cited by 8 publications

References 11 publications

Soluble IgE‐binding factors in the serum of food‐allergic patients: Possible pathophysiological role of soluble FcεRI as protective factor

Soluble IgE‐binding factors in the serum of food‐allergic patients: Possible pathophysiological role of soluble FcεRI as protective factor

New Frontiers: Precise Editing of Allergen Genes Using CRISPR

Current insights: a systemic review of therapeutic options for peanut allergy

Contact Info

Product

Resources

About